Overview
Work History
Education
Skills
Research Projects
Timeline
Generic
Qin Tian

Qin Tian

Overview

1
1
year of professional experience

Work History

Project Lead

SWIFF Antimicrobial Coating – Australian Market Entry
02.2024 - 11.2024
  • Strategic Execution: Led and optimized compliance processes under the Australian Industrial Chemicals Introduction Scheme (AICIS), ensuring all safety requirements were met and properly categorized
  • Risk Assessment: Independently conducted environmental and health risk assessments for silver chelate and tannic acid to meet US EPA standards, reducing pre-market risks
  • Documentation: Prepared and successfully submitted Safety Data Sheets (SDS) and Environmental Impact Reports (EIR) to meet Australian and international regulatory standards
  • System Development: Designed and implemented systematic record-keeping and monitoring systems to ensure post-launch compliance and enable quick regulatory responses
  • Strategic Adaptation: Monitored updates to AICIS and global regulations, adjusting compliance strategies to maintain competitiveness in a dynamic market

Project Lead

Unix Pathology Systems (UPS) Laboratory Relocation Project
08.2023 - 11.2023
  • Objective: Relocated the UPS laboratory to a new site with minimal disruption to client services
  • Key Responsibilities:
  • Developed detailed relocation plans, including timelines, budgets, and resource allocations
  • Oversaw facility design and equipment installation (e.g., ventilation systems, backup generators)
  • Implemented dual-site operation strategies to minimize downtime and ensure business continuity
  • Conducted risk assessments (e.g., data loss, equipment delays) and developed mitigation plans
  • Coordinated closely with stakeholders to ensure smooth project delivery
  • Outcomes:
  • Achieved seamless lab relocation and upgraded facilities with no service disruptions
  • Delivered a comprehensive report on relocation costs, timelines, and risk management frameworks for future reference

Team Member

Commercialization Potential Analysis of Star Polymer-siRNA Nanoparticles
08.2023 - 11.2023
  • Project Background: Evaluated the commercialization potential of star polymer-siRNA nanoparticles for lung cancer treatment
  • Key Contributions:
  • Conducted in-depth technical analysis and devised patent protection strategies to ensure long-term competitiveness
  • Proposed commercialization pathways (e.g., licensing agreements, company establishment) with financial viability assessments
  • Performed market and competition analysis to identify target customer groups and formulate differentiation strategies
  • Planned R&D costs, sales channels, and regulatory risks to ensure feasibility and sustainability of commercialization plans
  • Outcome: Delivered a detailed commercialization report outlining technology transfer paths and market potential, showcasing the investment value of the project

Education

Master of Biotechnology -

The University of Melbourne
12.2024

Bachelor of Science - Pharmacology

The University of Melbourne
12.2022

Skills

  • Microsoft Office Suite: Proficient in Word, Excel, PowerPoint, Outlook, etc
  • Data Analysis and Scientific Computing: Skilled in using R Studio for data analysis, statistical modeling, and visualization
  • Drug Development and Market Analysis: Theoretical knowledge of drug development processes, market research, and decision support
  • Risk Assessment and Regulatory Compliance: Familiar with risk assessment methodologies and regulatory compliance requirements for audits and risk management
  • Scientific Experiment Design and Data Analysis: Capable of designing experiments, analyzing data, and drawing valid conclusions
  • Languages: Native Mandarin speaker, fluent in English (listening, speaking, reading, writing) with strong cross-cultural communication skills

Research Projects

Jul 2022 – Nov 2022

Therapeutic Potential and Commercial Analysis of GPR139 Agonists for Parkinson’s Disease

Project Lead

Background: Addressed unmet clinical needs in Parkinson’s disease by exploring GPR139 agonists as a new therapeutic target.

Research Content:

• Validated efficacy by testing the effects of GPR139 agonists on neurotransmitter release and motor function improvement in Parkinson’s mouse models.

• Combined market demand and competitor analysis to evaluate the commercial potential of the drug.


Mar 2022 – Jun 2022

Effects of PDE3 and PDE5 Inhibitors on Rat Thoracic Aorta Relaxation

Project Lead

Background: Studied vascular smooth muscle relaxation to analyze the pharmacological effects of PDE3 and PDE5 inhibitors (Milrinone and Sildenafil) for drug development.

Research Content:

• Evaluated relaxation efficacy through ex vivo thoracic aorta ring experiments.

• Compared the regulatory effects of the two inhibitors on cAMP and cGMP signaling pathways to analyze mechanisms of action.


Timeline

Project Lead

SWIFF Antimicrobial Coating – Australian Market Entry
02.2024 - 11.2024

Project Lead

Unix Pathology Systems (UPS) Laboratory Relocation Project
08.2023 - 11.2023

Team Member

Commercialization Potential Analysis of Star Polymer-siRNA Nanoparticles
08.2023 - 11.2023

Bachelor of Science - Pharmacology

The University of Melbourne

Master of Biotechnology -

The University of Melbourne

Similar Profiles

CREATE PROFILE
Qin Tian